linjc16/ctgov huggingface dataset:
Effectiveness in Dental Plaque Reduction of Mouthwashes Containing Fatty Acids Compounds (F.A.G.) or Stannous Fluoride

Study Overview
=================
Brief Summary
-----------------
Comparative study on the efficacy of two mouthwashes Containing Fatty Acids Compounds (F.A.G.) or Stannous Fluoride in the reduction of plaque score in individuals with spontaneous gengivitis

Official Title
-----------------
Effectiveness in Dental Plaque Reduction of Two Mouthwashes Containing Fatty Acids Compounds (F.A.G.) or Stannous Fluoride: a Comparative Study

Conditions
-----------------
Gingivitis, Gingival Diseases

Intervention / Treatment
-----------------
* Drug: Fatty Acids Compounds (F.A.G.) Mouthwash
* Drug: Stannous Fluoride (SF) Mouthwash


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy individuals Exclusion Criteria: Smoking Drugs prior month Dental hygiene <6 months Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Fatty Acids Compounds (FAG)<br>Individuals taking FAG mouthwash | Drug: Fatty Acids Compounds (F.A.G.) Mouthwash<br>* Fatty Acids Compounds (F.A.G.) Mouthwash<br>|
| Active Comparator: Stannous Fluoride (SF)<br>Individuals taking SF mouthwash | Drug: Stannous Fluoride (SF) Mouthwash<br>* Stannous Fluoride (SF) Mouthwash<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in plaque score | Visual quantification of dental plaque amount on teeth buccal surfaces (wisdom teeth excluded). 0% = no visible plaque on teeth surfaces 100% = plaque visible on all teeth surfaces | Baseline; 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bleeding on Probing | Quantifying gingival bleeding after gentle gum manipulation assessed on 6 points per tooth (exluded wisdom teeth). 0% = No bleeding on all assessed points 100% = Bleeding on all assessed points | Baseline; 2 weeks |
Safety Study of a Refrigerator-stable Formulation of VARIVAX®

Study Overview
=================
Brief Summary
-----------------
Primary objective: To describe the safety profile of a refrigerator-stable formulation of VARIVAX® as a first single dose injection in 12 to 15 month-old infants in the 42-day follow-up period post-vaccination. Secondary objectives: NA

Official Title
-----------------
A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants.

Conditions
-----------------
Varicella, Measles, Mumps, Rubella

Intervention / Treatment
-----------------
* Biological: VARIVAX®
* Biological: M-M-RTM II


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy infants from 12 months of age to 15 months of age. Consent form signed by both parents or by the legal representative(s), properly informed about the study, Parent(s) able to understand the protocol requirements and to fill in the Diary Card. Exclusion Criteria: Prior receipt of measles, mumps, rubella or varicella vaccine either alone or in combination vaccine, Known or suspected clinical history of infection with measles, mumps, rubella, varicella or zoster, Any known recent (≤30 days) exposure to measles, mumps or rubella, Any known recent (≤30 days) exposure to varicella or zoster involving: Any recent (≤3 days) history of febrile illness (rectal temperature ≥38.0°C), Active untreated tuberculosis, Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems, Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity, Any previous (≤150 days) receipt of immune serum globulin or any blood-derived products or scheduled to be administered through visit 3, Any recent receipt of an inactivated or a live vaccine (≤ 30 days) or scheduled vaccination through visit 3

Ages Eligible for Study
-----------------
Minimum Age: 12 Months
Maximum Age: 15 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: VARIVAX®|nan|
|Biological: M-M-RTM II|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention of : Varicella, Measles, Mumps, Rubella
Iris Tissue in Primary Congenital Glaucoma

Study Overview
=================
Brief Summary
-----------------
To present the histopathological features of the iris tissue in primary congenital glaucoma which may play a role in pathogenesis

Detailed Description
-----------------
Primary congenital glaucoma etiology still remains obscure . originally barkan , and later Worst , proposed that a membrane covered the anterior chamber angle and blocked aqueous outflow , but the presence of that membrane has not been established histopathologically to date . Now most authors believe that the site of obstruction is the trabecular meshwork rather than an overlying membrane . Maldevelopment of the anterior segment is present in all forms of congenital glaucoma . this maldevelopment may involve the trabecular meshwork alone or the trabecular meshwork in combination with the iris or cornea or both. In approcimately 50% of patients , isolated trabeculodysgensis is the only developmental ocular anomaly found .This is the classic defect found in primary congenital glaucoma .These eyes have no developmental anomalies of iris or cornea present except abnormal insertion of the iris into the angle

Official Title
-----------------
Histopathological Examination of Iris Tissue in Primary Congenital Glaucoma

Conditions
-----------------
Primary Congenital Glaucoma

Intervention / Treatment
-----------------
* Procedure: Combined trabeculotomy-trabeculectomy with mitomycin c


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Typical symptoms of epiphora , photophobia and blepharospasm corneal diameter > 13 mm Increased ocular tension > 25 mmHg UGA using schiotz tonometer Exclusion Criteria: Infants with history of previous surgery Secondary glaucoma Glaucoma associated with other congenital anomalies

Ages Eligible for Study
-----------------
Minimum Age: 7 Days
Maximum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental : Infants with primary congenital glaucoma<br> | Procedure: Combined trabeculotomy-trabeculectomy with mitomycin c<br>* Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases then histopathological examination of iris tissue to detect the nature of the disease<br>* Other names: Histopathological examination of iris tissue;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Present histopathological features of iris tissue in infants with primary congenital glaucoma which may play a role in pathogenesis | Histopathological features of iris tissue in infants with primary congenital glaucoma who underwent Combined trabeculotomy-trabeculectomy with mitomycin C | 2 years |
Effects of High-Flow Nasal Cannula Therapy Assessed by Electrical Impedance Tomography

Study Overview
=================
Brief Summary
-----------------
This study aimed to determine the effects of HFNC therapy on lung recruitment and lung strain change assessed by electrical impedance tomography (EIT)

Official Title
-----------------
Effects of High-Flow Nasal Cannula Therapy on Lung Recruitment and Lung Strain Change Assessed by Electrical Impedance Tomography

Conditions
-----------------
High-flow Nasal Cannula, Electrical Impedance Tomography

Intervention / Treatment
-----------------
* Other: High-flow nasal cannula (HFNC)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who received a HENC therapy within 24 h after the extubation Exclusion Criteria: Aged <18 years Pregnancy Body mass index (BMI) over 50 kg/m2 ribcage malformation .any contraindication of using EIT monitoring (automatic implantable cardioverter defibrillator, chest skin injury, etc.).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: High-flow nasal cannula (HFNC)|24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lung regional ventilation distribution | lung regional ventilation distribution measured by EIT | minute 80 |
Influence of Depth of Anesthesia on Pupillary Reactivity to a Standardized Stimulus

Study Overview
=================
Brief Summary
-----------------
A standardized tetanic stimulation is applied to patients under propofol-remifentanil TCI, in a cross-over fashion, at two different levels of anesthesia monitored by the BIS: BIS 25 and BIS 55. Remifentanil target remains constant during the whole study period (1 ng/ml). Pupillary reflex dilation is recorded after each stimulation.

Official Title
-----------------
The Influence of Depth of Anesthesia on Pupillary Reactivity to a Standardized Stimulus Under Steady-state Remifentanil Analgesia

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Remifentanil
* Drug: propofol
* Device: TCI
* Procedure: Tetanic stimulation
* Device: Algiscan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA 1-2 scheduled for an idiopathic scoliosis surgical correction Exclusion Criteria: Ophtalmologic pathology Neurologic or muscular pathology Metabolic pathology Chronic pain

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BIS 55<br>Induction: TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg) Orotracheal Intubation Remifentanil target decreased to 1 ng/ml Propofol target adjustment to reach BIS 55 10 minutes steady state Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds Pupillary dilation recording (videopupillometer Algiscan) | Drug: Remifentanil<br> <br> Drug: propofol<br> <br> Device: TCI<br> <br> Procedure: Tetanic stimulation<br> <br> Device: Algiscan<br>* Pupillometry<br>|
| Active Comparator: BIS 25<br>Induction: TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg) Orotracheal Intubation Remifentanil target decreased to 1 ng/ml Propofol target adjustment to reach BIS 25 10 minutes steady state Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds Pupillary dilation recording (videopupillometer Algiscan) | Drug: Remifentanil<br> <br> Drug: propofol<br> <br> Device: TCI<br> <br> Procedure: Tetanic stimulation<br> <br> Device: Algiscan<br>* Pupillometry<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-stimulation Pupillary reflex dilation | percentage of dilation compared to pre-stimulation pupillary diameter | 30 seconds | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
analgesia, pupillometry, general anesthesia
A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This study is designed to assess a safe dosage of the drug CXL-1427 (BMS-986231) in healthy volunteers.

Official Title
-----------------
A First-in-Human Study of the Safety of Single Continuous Intravenous Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Drug: CXL-1427 Ascending Dose
* Other: Placebo
* Drug: CXL-1427 Descending Dose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No evidence of any acute or chronic health disorder Not have taken any prescription medication within 15 days of study entry Not have taken any over-the-counter medication or herbal/vitamin supplement within 3 days of study entry Not have not have any dietary restrictions Have a body mass index (BMI) of ≥18 to ≤34 Weigh at least 50kg (110 pounds) Exclusion Criteria: Be a current or recent (within 6 months of the Screening Visit) smoker or user of any nicotine-containing product Have a history of symptomatic hypotension, orthostatic hypotension or syncope Have a history of headaches or other symptoms attributable to caffeine withdrawal Have a history of any bleeding diathesis Have a positive serology screen for HIV antibody, hepatitis B surface antigen or hepatitis C antibody at screening Other protocol defined inclusion/exclusion criteria could apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CXL-1427 (BMS-986231)<br>Experimental | Drug: CXL-1427 Ascending Dose<br> <br> * Other names: BMS-986231;Drug: CXL-1427 Descending Dose<br> <br> * Other names: BMS-986231;|
| Placebo Comparator: Placebo<br>Placebo | Other: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety measured by percentage of Treatment Emergent Adverse Events (TEAEs) |  | Up to 31 days | 
| Tolerability measured by percentage of Treatment Emergent Adverse Events (TEAEs) |  | Up to 31 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Steady-state plasma concentration (Css) |  | Up to 4 days | 
| Area under the plasma concentration (AUC) vs. time curve |  | Up to 4 days | 
| Terminal elimination half-life (1/2) |  | Up to 4 days | 
| Total body clearance (CL) |  | Up to 4 days | 
| Steady-state volume of distributions (Vss) |  | Up to 4 days | 
| Time to Css |  | Up to 4 days |
Distalization Via Skeletally-anchored Distaljet Appliance With Two Approaches of Micro-osteoperforations

Study Overview
=================
Brief Summary
-----------------
study will be directed to evaluate two approaches of micro-osteoperforations during maxillary molar distalization.

Detailed Description
-----------------
Maxillary molar distalization via skeletally anchored distal jet appliance randomly divided into two equal groups

Official Title
-----------------
Appraisal of Two Different Approaches of Micro-osteoperforations During Maxillary Molar Distalization Via Skeletally-anchored Distaljet Appliance

Conditions
-----------------
Class II Division 1 Malocclusion

Intervention / Treatment
-----------------
* Device: skeletally anchored distal jet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion criteria: All patients should satisfy the following criteria:- Age range from 13-17 years. Bilateral Class II molar relationship. Skeletal Class I or mild Class II relationship. Normodivergent skeletal pattern No posterior crowding or diastemas. Fully erupted maxillary first and second molars. Congenitally missing or extracted third molars. Good oral and general health. No systemic disease/medication that could interfere with OTM. No previous orthodontic treatment. Exclusion Criteria: Exclusion criteria: Patient diagnosed to have an indication for non-extraction approach. Poor oral hygiene or periodontally compromised patient. Patient with craniofacial anomalies or previous history of trauma, bruxism or parafunctions. Previous orthodontic treatment

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: group(1)<br>Group I: will include ten patients undergo maxillary molar distalization using skeletally anchored distal jet appliance with MOPs that will be performed buccally on repeated basis on two sides before and during maxillary molar distalization | Device: skeletally anchored distal jet<br>* used from day one and activated every month<br>|
| Active Comparator: group(2)<br>Group II:will include ten patients undergo maxillary molar distalization using skeletally anchored distal jet appliance with MOPs that will be performed both buccally and palatally on repeated basis on two sides before and during maxillary molar distalization. | Device: skeletally anchored distal jet<br>* used from day one and activated every month<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in molar postion | using cephalometric x_ray for measurment | from start of treatment until study completion, an average of 1 year |
Clinical Significance of Computer Aided Image Analysis in Treatment Response Evaluation of Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The investigators will evaluate the utility of computer aided image analysis in lung cancer with the aim of predicting treatment response and prognosis.

Detailed Description
-----------------
Tumor biological behavior is the fundamental cause of heterogeneous prognosis. The features found on medical images are also reflections of the tumor biological behavior. However, the limitations in spatial and intensity resolution of the naked eye are two inevitable shortcomings of image interpretation by naked eyes, resulting in subjective and limited analyses of images. Computer aided image analyses such as radiomic analysis and machine learning methods are emerging as promising image interpretation methods. The natural advantage of the unlimited spatial and intensity resolution of computers can overcome the shortcomings of visual inspection with the naked eye. Moreover, the massive computing power of computer is also far greater than that of humans. This study will focus on the application of computer aided analysis in predicting treatment response and prognosis in lung cancer.

Official Title
-----------------
Clinical Significance of Computer Aided Image Analysis in Treatment Response Evaluation of Lung Cancer

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients >= 18 years old Pathological diagnosis of NSCLC between 2012 and 2019; PET/CT or CT examination before any cancer-specific treatment; Exclusion Criteria: A time interval between treatment and image examination greater than 1 month; A history of other malignancies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lung cancer patients<br>Lung cancer patients with PET/CT or CT examination before any cancer-specific treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | The interval between the date of diagnosis and death | 2012-2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival | The interval between the date of treatment initiation and disease progression | 2012-2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung cancer, Image, Treatment response, Prognosis, Radiomic, Deep learning